4‐stair climbing time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Weight gain · patients with Duchenne muscular dystrophy
1 finding from 1 review
Behavioural changes ‐ prednisone (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
Corticosteroids showed no clear difference in behavioural changes ‐ prednisone (0.75 mg/kg/day) compared with placebo (moderate certainty).
1 finding from 1 review
Fracture · patients with Duchenne muscular dystrophy
1 finding from 1 review
Improvement in sensory nerve function at 1 year · people with nerve damage (< 6 months' duration) in leprosy
Corticosteroids showed no clear difference in improvement in sensory nerve function at 1 year Defined as a… compared with placebo (moderate certainty).
1 finding from 1 review
Change in nerve pain and in nerve tenderness at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in activities of daily living at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in participation at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects requiring withdrawal/discontinuation of study medication · people with nerve damage (6 to 24 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as adverse events requiring withdrawal of… compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in motor nerve function at 1 year · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in nerve pain and in nerve tenderness at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in activities of daily living at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in participation at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events Assessed as: occurrence of one or more major adverse events requiring withdrawal of treatment · people with nerve damage (< 6 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as: occurrence of one or more major adverse… compared with placebo (moderate certainty).
1 finding from 1 review
1Small sample size. · people with nerve damage (< 6 months' duration) in leprosy
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Improvement in sensory nerve function at 1 year · people with nerve damage (6 to 24 months' duration) in leprosy
Corticosteroids showed no clear difference in improvement in sensory nerve function at 1 year compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in motor nerve function at 1 year · people with nerve damage (6 to 24 months' duration) in leprosy
1 finding from 1 review
Number of children with clinical adverse event: vertigo · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)
Corticosteroids showed no clear difference in vertigo compared with placebo (low certainty).
1 finding from 1 review
Dizziness Handicap Inventory score · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)
1 finding from 1 review
Caloric extent of recovery (improvement as a % in lateralisation of electronystagmography on caloric testing) · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)
2 findings from 1 review